Particle accelerators are essential tools for delivering excellence in many scientific fields and are widely used in industrial, healthcare and other applications. The demand of pushing further their scientific reach and of reinforcing their impact on society results in new challenges that must be addressed in the years to come: existing infrastructures are stretched to all performance frontiers, several world-class accelerator-based facilities on the ESFRI roadmap are under construction, and strategic decisions are needed for future accelerator facilities, to be realised on a global scale. To address these challenges, ARIES brings together a consortium of 41 beneficiaries from 18 countries: accelerator laboratories, technology institutes, universities and industrial partners to jointly address common challenges for the benefit of a number of projects and infrastructures in high-energy physics, as well as in photon and neutron science. By promoting complementary expertise, cross-disciplinary cooperation and a wider sharing of knowledge and technologies throughout academia and industry, ARIES will enhance the science and technology base for European accelerators. The main goals of ARIES are linked to developing and demonstrating novel concepts and further improving existing accelerator technologies, providing European researchers and industry with access to top-class accelerator research and test infrastructures, enlarging and further integrating the accelerator community in Europe, and developing a joint strategy towards sustainable accelerator S&T. ARIES comprises a strong industrial participation with 7 industrial partners, including two SMEs and one association. Innovation will be fostered by joint co-development programmes with industry, by supporting innovative technologies with market potential, and by advancing concepts and designs for medical, industrial and environmental applications of accelerators for the wide benefit of European science and society.

Proton beam therapy (PBT) is a radical new type of advanced radiotherapy, capable of delivering and conforming a targeted dose of radiation to the tumour while causing minimal damage to the surrounding healthy tissue. In the past 5 years there has been a huge investment in high energy PBT across Europe and eleven member states now either have PBT in operation or are developing this capability. In addition, the two largest manufactures of PBT equipment have based their manufacturing in Europe. This integrating activity INSPIRE, aims to link these clinical PBT centres in eleven different countries together with two associated centres in USA. It also brings in two of the worlds largest manufacturers of PBT equipment and an SME. The trans-national access in INSPIRE will provide European researchers with access to “state of the art” research capabilities employing proton beams at clinical energies. INSPIRE represents an integrating activity across Europe in a multi-disciplinary field that is growing exponentially. Through its Networking, Transnational Access and Joint Research Activities, INSPIRE seeks to provide the “state of the art” capabilities that are needed to address the key challenges in this rapidly developing field. INSPIRE has at its heart the principles of responsible research and innovation and will communicate its research and give access to its databases and software through an Open Access Gateway. INSPIRE will contain a pipeline of innovation through its Innovation Gateway, to accelerate research for patient and commercial benefit. INSPIRE will provide its researchers with an unrivalled research and training and opportunities to “discipline hop” into the industrial, clinical or industrial environment. INSPIRE integrates activities across Europe in this rapidly growing area and offers European researchers unrivalled access to state of the art research capabilities in an area where there has already been significant government investment.

Accelerate.EU, a collaborative European initiative, envisions revolutionising theranostics through innovative targeted alpha-therapies (TATs) using astatine-211. A unique consortium will combine diagnostics with potent cytotoxic effects of alpha-particles to enable precise tumour radiation while minimising side effects. Accelerate.EU's core objectives are: Innovate theranostic solutions based on therapeutic and diagnostic pairs for hard-to-treat cancers, exploring the potential for simultaneous preclinical studies and early-phase clinical trials (i.e. co-clinical approach) to showcase the enhanced benefits of these approaches for cancer patients. • Establish a robust and sustainable EU manufacturing and treatment infrastructure for astatine-211, ensuring compliance with quality assurance and regulatory guidelines while streamlining the supply chain across the EU. • Produce comprehensive educational and training content to support the deployment of theranostic solutions, fostering knowledge dissemination, transfer and longevity/durability Accelerate.EU strategically develop TATs to address unmet clinical needs in pancreatic, breast, and brain cancers. The co-clinical approach, incorporating concurrent clinical and preclinical studies, adds a breakthrough dimension to theranostics. Accelerate.EU pioneers 211At-theranostics establishing a resilient EU scale-up production network and empowering healthcare providers to offer TATs to cancer patients. Through the collaboration of experts from academia, industry and regulatory agencies, Accelerate.EU's implements a visionary approach addressing clinical gaps, accelerating TAT theranostic development, supporting EU global leadership, with primary target to improve patient outcomes for lasting impact on EU cancer care.